(Q40883582)

24 September 2017

Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain (English)

1 reference

24 September 2017

0 references

0 references

Richard L Rauck

1

1 reference

24 September 2017

Jeffrey Potts

2

1 reference

24 September 2017

Qinfang Xiang

3

1 reference

24 September 2017

Evan Tzanis

4

1 reference

24 September 2017

Andrew Finn

5

1 reference

24 September 2017

language of work or name

English

0 references

publication date

3 December 2015

1 reference

24 September 2017

Postgraduate Medicine

1 reference

24 September 2017

128

1 reference

24 September 2017

1-11

1 reference

24 September 2017

1

1 reference

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain

24 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

The prevalence of chronic pain in United States adults: results of an Internet-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Estimates of pain prevalence and severity in adults: United States, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

The economic costs of pain in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

A systematic review of the global prevalence of low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Opioids for low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Current knowledge of buprenorphine and its unique pharmacological profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Agonist and antagonist properties of buprenorphine, a new antinociceptive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

The Roland-Morris Disability Questionnaire and the Oswestry Disability Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Effect of nociceptin/orphanin FQ on the rewarding properties of morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Nociceptin/orphanin FQ and drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Opioids in chronic non-cancer pain: systematic review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1128307

10.1080/00325481.2016.1128307

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference